Neoadjuvant chemotherapy starts to show promising effects.
新辅助化疗也开始显示出良好疗效。
Complications of surgery were not increased by neoadjuvant chemotherapy.
新辅助化疗并未增加手术并发症。
In summary, this patient can be treated with adjuvant or neoadjuvant chemotherapy.
总之，这个患者可以进行辅助或新辅助化疗。
Purpose: To test the safety of neoadjuvant chemotherapy for resectable pancreatic cancer.
目的：验证可手术胰腺癌新辅助化疗的安全性。
Objective To study the clinical effect of neoadjuvant chemotherapy on advanced breast cancer.
目的探讨新辅助化疗在晚期乳腺癌治疗中的效果。
In the validation group, 165 of 198 patients received all chemotherapy as neoadjuvant treatment.
在确认组(？)，198名中的165名患者接受了新辅助化疗。
Objective: To evaluate the significance of neoadjuvant chemotherapy in elder breast cancer patients.
目的：探讨新辅助化疗在老年乳腺癌患者治疗中的意义。
Neoadjuvant chemotherapy can reduce tumor loading, degrade the staging, afford operation possibility.
新辅助化疗能减少肿瘤负荷，降低原发肿瘤分期，增加手术切除的可能性。
Objective: To investigate the effect of TP for neoadjuvant chemotherapy on locally advanced cervical cancer.
前言：目的：探讨紫杉醇联合顺铂(TP)对局部晚期宫颈癌新辅助化疗的临床效果。
The present status of neoadjuvant chemotherapy for the treatment of gastric cancer was reviewed in this article.
该文主要对近年来新辅助化疗在胃癌治疗中的现状进行了综述。
Objective: To evaluate the effect of neoadjuvant chemotherapy in the treatment of locally advanced breast cancer.
前言： 目的：探讨新辅助化疗在局部晚期乳腺癌治疗中的应用。
This review presents the present state and future prospect of neoadjuvant chemotherapy for advanced breast cancer.
现就新辅助化疗在乳腺癌治疗中的现状及展望作一综述。
Conclusion: the combination of paclitaxel and cisplatin was an effective regimen as neoadjuvant chemotherapy for LAEC.
结论：紫杉醇联合顺铂新辅助化疗方案治疗中晚期食管癌疗效显著。
Neoadjuvant chemotherapy can minish burthen of tumor and lower the clinical stage, and increase resection rate of cancer.
新辅助化疗可以减小肿瘤负荷，降低临床病期，提高肿瘤的手术切除率。
In the discovery cohort, 227 biopsy samples were obtained, and all chemotherapy was administered as neoadjuvant treatment.
发现队列(？)中，有227分活检样本被检测，所有化疗被作为新辅助化疗而处方。
To investigate, the researchers studied stage II and II breast cancer patients who were receiving neoadjuvant chemotherapy.
研究人员对接受新辅助化疗的II期乳腺癌患者进行了研究。
Methods: 32 patients with locally advanced breast cancer treated by neoadjuvant chemotherapy were reviewed retrospectively.
方法：回顾性分析32例局部晚期乳腺癌患者进行新辅助化疗的临床资料。
Objective to evaluate the efficacy of Paclitaxel in treatment of soft-tissue sarcoma receiving the neoadjuvant chemotherapy.
目的分析紫杉醇应用于软组织肉瘤的疗效。
The results also indicate that a complete response to neoadjuvant endocrine therapy is rare compared to neoadjuvant chemotherapy.
这项研究结果也显示，相比较新辅助化疗，罕见对新辅助内分泌治疗有完全的缓解。
Several chemotherapeutic agents have proven to be useful as neoadjuvant or adjuvant treatment and in patients with metastatic disease.
目前已证实，几种化疗药可作为某些转移性癌症患者的新辅助治疗或辅助治疗药。
Nowadays, neoadjuvant chemotherapy, which is raised by clinic, made a big breakthrough in breast cancer partial treatment progression.
乳腺癌术前化疗即新辅助化疗，使局部进展期乳腺癌的治疗取得了重大进展。
Results: After neoadjuvant chemotherapy, 30 patients got partial response and some of the primary inoperable lesions became vespectable.
结果：32例患者中30例经辅助化疗后病情缓解，可以手术。
Conclusions: Neoadjuvant chemotherapy can induce tumor cell apoptosis and inhibit tumor cell proliferation in patients with breast cancer.
结论：新辅助化疗能诱导人体乳腺癌肿瘤细胞发生凋亡，并能抑制其增殖。
Objective To evaluate the clinical value of neoadjuvant chemotherapy for breast cancer on pathological stage and designing of therapy plan.
目的通过研究新辅助化疗对乳腺癌根治术后病理分期及治疗方案的影响，进一步评价新辅助化疗的临床价值。
Conclusion: Neoadjuvant chemotherapy with gemcitabine and cisplatin is well tolerated and does not impair resectability of pancreatic cancer.
结论：吉西他滨联合顺铂的新辅助化疗耐受性好，并且没有破坏胰腺癌的可手术性。
Methods 73 patients with cervical cancer were examined by ultrasonography before and after surgery, radiotherapy or neoadjuvant chemotherapy.
方法73例宫颈癌患者在化疗、放疗、术前、术后应用超声方法进行检查。
Previous research suggests that neoadjuvant treatment with irinotecan- or oxaliplatin-based chemotherapy can make surgery more likely to succeed.
先前的研究显示以伊利替康或奥沙利铂为基础的化疗可以增加手术切除机会。
AIM: To investigate the expression of drug resistance genes, MDR1 and MRP, in patients with primary breast cancer after neoadjuvant chemotherapy.
目的：探讨乳腺癌新辅助化疗对耐药基因mdr1和MRP表达的影响。
AIM: To investigate the expression of drug resistance genes, MDR1 and MRP, in patients with primary breast cancer after neoadjuvant chemotherapy.
目的：探讨乳腺癌新辅助化疗对耐药基因mdr1和MRP表达的影响。
应用推荐